A 2020 meta-analysis examining the use of GLP-1 RAs in the treatment of pediatric obesity and/or T2DM found mild gastrointestinal symptoms to be the most common side effects and no episodes of severe hypoglycemia [24]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.